Bristol Myers Squibb

• 1. Foundations And Civil War Era

  ›

  In 1858, Edward Robinson Squibb opened a small laboratory in Brooklyn, New York. He began selling pure medical supplies to doctors who demanded higher standards than the industry offered at that time. The American Medical Association refused his request for stricter purity rules, so he published his own alternative titled Squibb's Ephemeris of Materia Medica. His early work appeared in over one hundred papers within the American Journal of Pharmacy during the late 1800s. When the American Civil War erupted, Squibb became a critical supplier for the Union Army. He provided portable medical kits containing morphine and surgical anesthetics to field hospitals across the Eastern United States. Quinine was included in these shipments to treat malaria, which remained endemic throughout much of the region. This supply chain established the company's reputation for quality control before it even had a formal corporate structure.

• 2. Bristol Myers Evolution

  ›

  Hamilton College graduates William McLaren Bristol and John Ripley Myers purchased the Clinton Pharmaceutical company in 1887. They renamed the business Bristol, Myers and Company in May 1898 after Myers died the following year. The new corporation introduced Sal Hepatica, a laxative mineral salt, as its first nationally recognized product during the 1890s. Ipana toothpaste followed in 1901, becoming another household name under their brand umbrella. Additional divisions included Clairol hair colors and Drackett household products like Windex and Drano. In 1943, the firm acquired Cheplin Biological Laboratories in East Syracuse, New York. They converted that plant to produce penicillin for World War II Allied forces. After the war ended, they renamed the facility Bristol Laboratories and entered the civilian antibiotics market. Penicillin production at the East Syracuse plant ceased in 2005 when overseas manufacturing became cheaper.

• 3. The Great Merger Of 1989

  ›

  Bristol-Myers and Squibb officially merged in 1989 to form Bristol-Myers Squibb. This consolidation created one of the largest pharmaceutical entities in the United States. President Bill Clinton awarded the combined company the National Medal of Technology in 1999. The citation honored their work extending human life through innovative pharmaceutical research and development. It also praised their groundbreaking clinical trials that became recognized models within the industry. The company maintained primary research sites in Lawrence, Summit, and New Brunswick, all located in New Jersey. Additional facilities existed in Redwood City, California, and Seville, Spain. Other locations included Devens and Cambridge, Massachusetts, Braine-l'Alleud, Belgium, Tokyo, Japan, Hyderabad, Bangalore, India, and Wirral, United Kingdom. A former site in Wallingford, Connecticut, closed its operations as part of later restructuring efforts.

• 4. Scandals And Corporate Restructuring

  ›

  In July 2006, the FBI raided corporate offices on charges of collusion regarding Plavix distribution. Federal Judge Frederick B. Lacey urged CEO Peter Dolan to step down following the investigation. Dolan announced his resignation later that same day. Under Jim Cornelius, who served as CEO from May 2010 until 2010, executives involved in channel-stuffing scandals left the firm. The deferred prosecution agreement expired in June 2007 without further legal action. In 2009, the company began a major restructuring focused on biologic products and pharmaceutical business lines. They launched a multiyear program involving ongoing layoffs and cost-cutting measures. Half of their manufacturing facilities were closed during this strategic transformation period. Bristol-Myers Squibb also reduced healthcare subsidies for retirees and froze pension plans at the end of 2009. Lamberto Andreotti became CEO in 2010 after previously serving as president and COO.

• 5. Aggressive Acquisition Strategy

  ›

  August 2019 saw the acquisition of Celgene for $74 billion or $95 billion including debt. This deal aimed to refresh the pipeline against declining sales of Opdivo relative to competitor Keytruda. Seventy-five percent of shareholders voted to approve the merger despite opposition from Wellington Management Company and Starboard Value. February 2020 brought the purchase of MyoKardia for $13.1 billion, gaining control of mavacamten for obstructive hypertrophic cardiomyopathy. August 2022 included acquiring Turning Point Therapeutics for $4.1 billion to boost cancer drug portfolios with repotrectinib. January 2024 marked the acquisition of Mirati Therapeutics for $4.8 billion plus an additional $1 billion milestone payment. March 2024 finalized the purchase of Karuna Therapeutics for $14 billion, adding KarXT for schizophrenia treatment. These acquisitions reshaped oncology and psychiatry pipelines while divesting consumer health businesses like UPSA to Taisho Pharmaceutical in July 2019.

• 6. Financial Performance And Global Reach

  ›

  In 2024, Apixaban generated 28% of total revenues while nivolumab contributed 19%. Lenalidomide accounted for 12% of revenue, followed by abatacept at 8%. Pomalidomide and ipilimumab each represented 8% and 5% respectively, with luspatercept making up 4%. Seventy-one percent of all company revenues originated from the United States that year. The firm ranked 94th on the Fortune 500 list and 173rd on the Forbes Global 2000. Revenue figures fluctuated between 15.62 billion dollars in 2007 and 46.39 billion dollars in 2021. Net income varied significantly, dropping to negative 9.02 billion dollars in 2020 before recovering to 6.99 billion in 2021. Employee counts ranged from 23,300 in 2018 to 34,300 in 2022. The company spent five to ten million dollars annually on lobbying efforts within the United States.